S U M M A R Y S E T T I N G :
Despite the widespread introduction of Xpert w MTB/RIF in developing countries, reports of its use and value in routine conditions remain limited. O B J E C T I V E : To describe Xpert results in relation to microscopy, treatment initiation, cost and workload under routine conditions at four sites in Cambodia, Georgia, Kenya and Swaziland. D E S I G N : Laboratory and clinical information on presumed TB patients were obtained from routine registers over a period of at least 6 months between March and November 2012. R E S U LT S : Among the 6086 presumed TB patients included in the analysis, Xpert testing increased the number of biologically confirmed cases by 15% to 67% compared to microscopy. Up to 12% of the initial Xpert results were inconclusive. Between 56% and 83% of patients were started on treatment based on microscopy and/or Xpert results, with median delays of 1-16 days. Rifampicin resistance was detected in 3-19% of Xpertpositive patients. C O N C L U S I O N : Despite the additional numbers of cases detected by Xpert compared to microscopy, large proportions of patients are still started on treatment empirically in routine practice. Patient and specimen flow should be optimised to reduce delays in treatment initiation. Simple, non-sputum-based point-of-care tests with high sensitivity are needed to improve TB diagnosis and management. K E Y W O R D S : diagnostic test; cost; tuberculosis; routine conditions TUBERCULOSIS (TB) REMAINS the second most common cause of death due to an infectious agent worldwide, and approximately one third of all TB cases are believed to go undetected due to the poor sensitivity of current diagnostic techniques. 1 The recent introduction of an integrated molecular assay for the diagnosis of TB and detection of rifampicin (RMP) resistance has opened new perspectives. This test, the Xpert w MTB/RIF assay (Cepheid, Sunnyvale, CA, USA), shows a sensitivity of respectively 86% and 79% compared to culture in human immunodeficiency virus (HIV) negative and -positive patients, and a specificity of 98%, according to a meta-analysis of published studies. 2 It is easy to use and provides results in ,2 h, thus facilitating decentralised and same-day testing. 3 The World Health Organization (WHO) recommends using Xpert as the initial diagnostic test instead of microscopy in adults presumed to have HIV-associated or multidrug-resistant TB (MDR-TB). 4, 5 In other patients, the current policy recommends using Xpert either as the initial diagnostic test or as an add-on test following a negative microscopy result, where resources are available. In practice, many facilities use Xpert as an add-on test. 6 Recent studies on how the introduction of Xpert impacts patient outcomes have shown increases in same-day diagnosis, but limited or no benefit in terms of proportions of patients on treatment, morbidity or mortality. [7] [8] [9] [10] This apparent lack of impact may reflect the high proportion of patients started on treatment empirically, without laboratory confirmation, and/or difficulties in defining and adopting diagnostic and treatment algorithms. 11 The impact might be even lower in routine conditions, where there are other additional challenges, such as lack of national guidance on testing algorithms, high rates of failed tests and delays in testing, that prevent sameday diagnosis; however, routine data remain scarce. 6 Here, we present data on the use of Xpert under routine conditions in four TB programmes in different settings as regards HIV prevalence and MDR-TB risk. We report on per-patient analysis of Xpert results when compared to microscopy, treat-ment initiation and delay, as well as cost and workload issues.
STUDY POPULATION AND METHODS

Sites and population
The analysis was conducted on routine data collected from four TB programmes supported by Médecins Sans Frontières (MSF) in Kampong Cham, Cambodia, Sukhumi, Georgia, Mathare, Kenya, and Nhlangano, Swaziland. These sites were non-randomly selected to illustrate settings with different human immunodeficiency virus (HIV) prevalence and multidrug-resistant TB (MDR-TB) risks (Appendix Table  A .1).* All sites had been using the Xpert assay for at least 6 months prior to the start of data collection to ensure that data reflected established routine use.
The laboratory received specimens from the health structure where it was located, as well as from peripheral health centres or clinics (Appendix Table  A .1). The population consisted of all patients presumed to have TB for whom at least one diagnostic specimen was sent to the laboratory. Patients started on treatment without providing a diagnostic specimen were also included based on data collected in the clinical register. There was no minimal sample size for this descriptive study.
In high HIV prevalence settings (Mathare and Nhlangano), the recommended definition of a presumed TB patient was cough for .2 weeks; or any cough with at least one of the following signs: weight loss, night sweat, fever; or suspicion based on clinical judgment. The diagnostic algorithm included Xpert testing for all presumptive TB patients and repeated testing for patients with presumed TB who are initially negative and not recovering on broadspectrum antibiotics.
In low HIV prevalence settings (Kampong Cham and Sukhumi), the recommended definition of a presumed TB patient was cough for .2 weeks. The diagnostic algorithm was smear microscopy as firstline test and Xpert testing for patients at high risk of MDR-TB or smear-negative suspects not recovering on broad-spectrum antibiotics. In addition, in high MDR-TB settings (Sukhumi), all smear-positive patients were tested with Xpert to assess RMP resistance.
When anti-tuberculosis treatment is initiated on clinical grounds, the MSF guidelines do not recommend stopping treatment if subsequent laboratory test results are negative.
Microscopy and culture
Smear microscopy was performed by experienced technicians at all sites. Auramine fluorescence microscopy using light-emitting diode-based microscopes on two sputum samples were used at all sites except for Sukhumi, where three sputum samples were submitted for Ziehl-Neelsen staining. Positive slides were read and graded according to WHO guidelines. 12 In Kampong Cham, Löwenstein-Jensen and MGITe (Mycobacteria Growth Indicator Tube, BD, Sparks, MD, USA) cultures were performed systematically, each on one specimen submitted for microscopy. In Nhlangano, thin-layer agar (TLA) culture was started during the monitoring period on a limited number of specimens.
Cost estimation
Test costs were estimated based on the current cost of Xpert cartridges by MSF-Logistique (excluding shipment costs), plus additional costs of materials as needed, as reported by the field sites. Staff cost was calculated by multiplying the time spent on each test (estimated at approximately 15 min) by hourly wages. The cost per test was multiplied by the average number of tests per patient to obtain a testing cost/patient. Microscopy costs were not reported here, but a generic cost of E2.7/patient was considered based on published data from an MSF-supported site. 13 Data collection and analysis Data collected from the laboratory and clinical registers were entered into an Excel file (MicroSoft, Redmond, WA, USA) designed for routine monitoring. Data were analysed using Stata w 12.1 (StataCorp, College Station, TX, USA). Patients were identified by a unique identification number.
The relative gain of Xpert was defined as the ratio between the number of smear-negative patients detected using Xpert and the number of smearpositive patients.
Ethics
The protocol was submitted to the MSF ethical review board (Geneva, Switzerland), which waived the need for ethics approval, as this was a quality assurance study that used routine anonymised data for analysis. Table  A .2).
RESULTS
Description of the study population
There were differences in the population characteristics among sites, with a higher proportion of males in Sukhumi, younger age in Mathare and Nhlangano, and a higher proportion of presumptive extra-pulmonary cases in Kampong Cham (Appendix Table A .2). Among patients started on treatment, retreatment cases represented more than one in five patients in Mathare and Sukhumi (Appendix Table  A .
2).
Xpert results and relative gain over microscopy in high HIV prevalence settings
In Mathare and Nhlangano, almost all patients underwent at least one Xpert test; the proportion of those with two or three Xpert tests varied from 2.9% in Nhlangano to 13.5% in Mathare (Appendix Table  A .2). At both sites, the main reason for repeating the Xpert test was that the initial test was inconclusive (error, invalid, no result: 123/145, 84.8%, in Mathare and 62/76, 81.6%, in Nhlangano), followed by repeated testing for presumed TB patients not recovering on broad spectrum antibiotics (n ¼ 17, 11.7% in Mathare; n ¼ 6, 7.9% in Nhlangano).
The proportion of inconclusive initial results was 12.2% in Mathare and 7.0% in Nhlangano; this decreased to respectively 4.3% and 4.2% after repeated testing. The proportion of Xpert-positive, smear-negative patients was higher among HIVpositive than among HIV-negative patients at the two sites, and higher in Nhlangano than in Mathare (Figure 1 ), with relative gains over microscopy of respectively 28.8%, 9.7% and 15.5% in HIVpositive, HIV-negative patients and overall in Mathare, and 79.2%, 58.8% and 66.7% in Nhlangano.
Reasons for performing Xpert and additional yield in low HIV prevalence settings In the low HIV prevalence settings, the proportion of patients tested with Xpert was 39.5% in Sukhumi and 54.6% in Kampong Cham (Appendix Table A .2). The main reasons for requesting Xpert are presented in Table 1 . The proportions of Xpert-positive patients among those tested was respectively 30.3% (88/290) The proportion of additional cases detected using Xpert compared to microscopy by setting and type of request is presented in Figure 2 . The relative gain was 17.8% in Sukhumi and 24.2% in Kampong Cham.
Patients on treatment
The proportion of patients confirmed by microscopy, Xpert or both varied between 56% and 83% among adult pulmonary TB patients started on treatment and from 6% to 26% among adult extra-pulmonary TB patients ( Table 2 ). The time between the collection of the first specimen and treatment start varied substantially across sites and type of biological confirmation (Table 2) . Figure A) .
Rifampicin resistance
Cost
At a cost of E9.19 per cartridge, we estimated that the cost/patient detected varied between E32.8 and E91.4 across sites (Appendix Table A. 3). Around 80% and 92% of the total costs were for testing smear-negative patients in Mathare and Nhlangano, respectively. If we assume a cost of E2.7/patient for microscopy, the total cost/patient detected would have been respectively E51.3 and E96.3 had Xpert been used as an add-on test to microscopy in Mathare and Nhlangano.
DISCUSSION
The results of Xpert use in these four programmes illustrate the variety of use and added value of Xpert compared to traditional methods depending on the context and the algorithm used. As expected, given its widely demonstrated greater sensitivity, 2,3 Xpert detected more TB cases than microscopy overall. In high HIV prevalence settings, the relative gain of Xpert compared to microscopy in initial patient screening varied greatly between Mathare and Nhlangano, but was within the wide range of relative gains reported by MSF or calculated in a multicentric implementation study by other authors (7% to 150%). 14 The reasons for such variations are unclear, but could include several factors such as differences in populations attending the clinics in terms of HIV prevalence and health care use, which could also explain the difference in the proportions of smearpositive patients between the two sites. Differences in microscopy sensitivity could also be a reason. Despite the additional number of cases detected by Xpert, a large proportion of patients were started on treatment empirically at all sites. In Nhlangano, most of these patients were started on the day of first specimen collection, suggesting that the clinicians did not wait for the biological results. This might be partly due to the suboptimal turnaround times to obtain results, which also delayed treatment start for laboratory-confirmed patients. Several reasons could have contributed to these laboratory delays, including high workload, preparation of specimens for culture at sites performing both methods in parallel, as well as the complexity of the diagnostic algorithm at sites that did not perform Xpert systematically. Same-day testing in the laboratory should be ensured to reduce delays in treatment initiation and loss to follow-up. 15 Adherence to the recommended use of Xpert was low in both high and low HIV prevalence settings. In high prevalence settings, only a few patients underwent a repeat Xpert after broad-spectrum antibiotic treatment, probably due to the complexity of following the algorithm in the absence of well-kept clinical files for presumptive TB patients, as reported informally by clinicians on site. In low HIV prevalence settings, many smear-negative patients were tested prior to broad-spectrum antibiotic treatment, against recommendations. It is difficult to restrain clinicians from using an efficient tool where available. As a consequence, the added value of these strategies could not be evaluated, and the global added value of the diagnostic algorithm using Xpert might have been underestimated.
Although it was not possible to evaluate the impact of introducing Xpert on treatment initiation or outcomes due to the lack of comparative data in our settings, the large proportion of patients started on empirical treatment might have undermined this effect, as reported elsewhere. 11 However, considering the imperfect sensitivity of Xpert, we believe that empirical treatment is still justified in certain cases, and that this does not undermine the added value of Xpert in increasing biological confirmation of TB diagnosis. In addition, the median delay of 10-17 days in initiating MDR-TB treatment among RMPresistant TB patients probably represents a real improvement over the pre-Xpert era, as suggested by the long delays in obtaining conventional DST results at some sites.
Modelled costs of using Xpert as a replacement or add-on test after microscopy were very similar in Mathare and Nhlangano, arguing in favour of the simpler and less time-consuming use of Xpert only as initial test whenever possible. However, considering the high rate of inconclusive results reported here and elsewhere, 6 some smear-positive cases might be missed by this strategy and a system should be in place to ensure second specimen collection to repeat Xpert and reduce the number of inconclusive results.
Routine data collection represents the main strength of this study, providing valuable data to document the use of Xpert in a real-life situation, but also its main weakness. Some data on screening and clinical information were missing or lacking in precision. In particular, the identification of patients providing several specimens for diagnosis was difficult, and reasons for requesting Xpert in low HIV prevalence settings were sometimes imprecise. In addition, our data did not include the date the results were made available to clinicians, probably leading to an underestimation of the proportion of patients started on treatment without laboratory confirmation.
In conclusion, these data confirm the added value of Xpert compared to microscopy for the biological confirmation of TB and detection of RMP resistance, although with considerable variations across different sites. However, the proportion of patients put on empirical treatment remained high, and most extra-pulmonary cases were still not confirmed. The organisation of patient, specimen and result flow should be optimised to ensure same-day testing in the laboratory and reduce the time to treatment initiation. Diagnostic and clinical algorithms should be as simple as possible, and training should focus on both clinicians and laboratory staff to ensure optimal adherence. Where budget allows, Xpert should be considered as the initial test and not as an add-on test to microscopy, as the latter strategy is not costeffective. Finally, non-sputum-based point-of-care diagnostic tests are still needed for rapid diagnosis of TB, particularly in extra-pulmonary patients and children. 
R E S U M E N M A R C O D E R E F E R E N C I A:
Pese a la introducción generalizada de la prueba Xpert w MTB/RIF en los países en desarrollo, existen aún pocos datos fidedignos sobre su uso y sus ventajas en las condiciones de la prá ctica corriente. O B J E T I V O: Describir los resultados obtenidos con la prueba Xpert, en comparación con el examen microscópico, la iniciación del tratamiento, los costos y la carga de trabajo en las condiciones de la prá ctica ordinaria en cuatro centros en Camboya, Georgia, Kenya y Swazilandia. M É T O D O: Se obtuvo información de laboratorio y datos clínicos de los pacientes con presunción diagnóstica de tuberculosis (TB) a partir de los registros sistemá ticos durante un período mínimo de 6 meses de marzo a noviembre del 2012. R E S U LTA D O S: En los 6086 pacientes con presunción clínica de TB que se incluyeron en el aná lisis, la prueba Xpert aumentó de 15% a 67% la proporción de casos confirmados bacteriológicamente en comparación con el examen microscópico. Hasta un 12% de los resultados iniciales de la prueba fueron no concluyentes. Del 56% al 83% de los pacientes que recibían tratamiento lo habían iniciado con base en la baciloscopia, la prueba Xpert o ambas, con una mediana del retraso de 1 a 16 días. Se detectó resistencia a rifampicina en 3% a 19% de los pacientes con resultado positivo a la prueba Xpert. C O N C L U S I Ó N: Si bien la prueba Xpert aumentó el número de casos detectados en comparación con la baciloscopia, en la prá ctica corriente una gran proporción de pacientes comienza aun el tratamiento con bases empíricas. Es preciso optimizar el flujo de los pacientes y las muestras, con el propósito de disminuir el retraso en el comienzo del tratamiento. Se necesitan pruebas diagnósticas inmediatas en el punto de atención y que sean sencillas y muy sensibles a fin de mejorar el diagnóstico y el tratamiento de la TB.
